Changes in Metabolic, Inflammatory and Coagulation Biomarkers after HIV Seroconversion – the Health in Men (Him) Biomarker Substudy. Issue 3 (April 2013)

• Record Type: Journal Article
• Authors: Achhra, Amit C; Amin, Janaki; Law, Matthew G; Grulich, Andrew E; Yeung, Julie; Kelleher, Anthony D; Cooper, David A
• Is Part Of: Antiviral therapy. Volume 18:Issue 3(2013)
• Page Start: 355
• Page End: 359
• Publication Date: 2013-04
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP2434
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: Biomarkers of inflammation, coagulation, lipids and vitamin D have been associated with cardiovascular and mortality risk in HIV-infected individuals. Scarce data exist on changes in these markers from pre-to post-HIV seroconversion. Methods: The study participants were drawn from the Health in Men Study, which recruited HIV-negative homosexual men. Participants with incident HIV infection ( n =26) were compared with HIV-negative controls ( n =52) matched on age at enrolment, date of visit and reported intravenous drug use. Levels of metabolic (lipids and vitamin D), inflammatory (C-reactive protein and interleukin-6) and coagulation (D-dimer and fibrinogen) biomarkers were measured at pre- and post-HIV seroconversion visits and corresponding visits for controls. Random-effect models were used to compare changes in markers between cases and controls. Results: The median gap between pre- and post-seroconversion or matched first and second visits in controls was 12 months. HIV seroconversion was associated with decline in high density lipoprotein (HDL-C; difference in mean change between cases and controls -0.14 mmol/l; 95% CI -0.22, -0.01; P =0.035). There were no significant differences in changes in other lipids, markers of inflammation, coagulation or vitamin D. Conclusions: Decline in HDL-C seems to be the main proatherogenic change within 1–1.5 years after HIV seroconversion. HIV seroconversion was not associated with profound changes in other lipids, or markers of inflammation, coagulation and vitamin D. Longitudinal assessment of these markers in comparable population needs further assessment.